Status:
UNKNOWN
Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric Cancer
Lead Sponsor:
Chinese Academy of Medical Sciences
Conditions:
Gastric Cancer
Concurrent Chemoradiotherapy
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The prognosis of patients with inoperable locally advanced or residual/relapsed gastric cancer is rather poor. Concurrent capecitabine chemoradiotherapy is safe and recommended. Nimotuzumab, an anti-E...
Detailed Description
There is no standard treatment for patients with inoperable locally advanced or residual/relapsed gastric cancer. For the former ones, 5-fluorouracil(5-FU) based concurrent chemoradiotherapy is a reco...
Eligibility Criteria
Inclusion
- 18-75 years old, male or female
- Gastric cancer with measurable lesions, and the diameter is at least 1 cm
- Karnofsky score: at least 70
- Estimated survival: at least 6 months
- No prior target therapy or radiotherapy
- No severe hypertension, cardiac disease, or diabetes mellitus
- Normal blood routine and chemical tests
- Signed consent
Exclusion
- Other malignancies simultaneously except in situ cervix or non-melanoma skin cancer
- Extensive distant metastases
- Pregnancy or in lactation
- Allergic to 5-Fluorouracil
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2013
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01180166
Start Date
May 1 2010
End Date
September 1 2013
Last Update
September 19 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021